1,157,852 shares: the quorum Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) needed to transact business at its adjourned special stockholder meeting on August 19, 2026, per an 8-K filed with the SEC that day. The filing defines that threshold as one-third of the 3,473,554 shares of common stock outstanding and entitled to vote on the April 28, 2026 record date. Holders fell short, prompting the Chairman to cancel the meeting; the company said it will not solicit additional proxies.
The definitive proxy statement had been filed with the SEC on May 5, 2026, placing the process more than three months in motion before the August session. The August 19 meeting was itself an adjournment of an earlier sitting. With the company declining to pursue further solicitation, the matter will not come to a fresh stockholder vote through this process.
The 8-K does not name the matter or matters put before stockholders. It was signed by Chief Executive Officer Amy Trombly. Sonoma Pharmaceuticals is incorporated in Delaware, headquartered at 5445 Conestoga Court in Boulder, Colorado, and lists its common stock on Nasdaq under the ticker SNOA.